Coronary Stent Market to Reach $11.3B by 2031 Amid VBP Stabilization and DES Dominance
Date : 2026-11-09
Reading : 476
Global Coronary Stent Market Value Approaches $11.3 Billion by 2031: HDIN Research Evaluates Value Migration, Procurement Shifts, and Next-Generation Scaffolds
According to primary field audits and supply-side econometric modeling published today by HDIN Research, the global coronary stent market is valued between US$7.2 billion and US$8.2 billion in 2026. Expanding at a compound annual growth rate (CAGR) of 4.6% to 6.6%, aggregate industry revenues are projected to reach between US$9.0 billion and US$11.3 billion by 2031. Growth across the intervention sector remains anchored by an escalating global burden of cardiometabolic indications and demographic aging, with global procedural volume heavily bolstered by the Asia-Pacific territory—where annual Percutaneous Coronary Intervention (PCI) procedures in China surpassed 2.0 million cases in 2025.
Technological Moats and the Monolithic Reign of Drug-Eluting Stents
Clinical deployment metrics compiled by HDIN Research confirm that Drug-Eluting Stents (DES) command more than 98% of all percutaneous coronary revascularizations worldwide. Bare Metal Stents (BMS), constructed from unmedicated 316L stainless steel or cobalt-chromium (CoCr) structures, have fallen below 1–2% market volume due to historic 12-month in-stent restenosis (ISR) profiles tracking between 10% and 30%.
The technological baseline has consolidated around thin- and ultra-thin-strut metallic architectures (CoCr and platinum-chromium) delivering antiproliferative macrocyclic lactones ('limus class agents, including sirolimus, everolimus, zotarolimus, and biolimus A9). Multi-tiered technical moats separate established market incumbents from regional commodity producers:
* Durable vs. Bioresorbable Coatings: While durable fluoropolymer platforms such as Abbott Vascular’s XIENCE and Medtronic’s Resolute Onyx maintain clinical trust, structural innovation has rotated toward abluminal bioresorbable polymers. Platforms like MicroPort’s Firehawk (target-eluting laser grooves) and Sino Medical’s BuMA minimize systemic carrier exposure to accelerate long-term vessel healing.
* Polymer-Free Solutions for High Bleeding Risk (HBR): Solutions such as Bluesail Medical’s BioFreedom Ultra deploy biolimus A9 via micro-structured metallic surfaces without polymer carriers, securing regulatory validation for abbreviated 1-month dual antiplatelet therapy (DAPT).
* Bioresorbable Scaffolds (BRS): Following the 2017 global market withdrawal of Abbott's early thick-strut Absorb BVS, the "intervention without implantation" segment is restructuring. Lepu Medical’s NeoVas (PLLA scaffold) retains an NMPA Class III footprint in China, while next-generation metallic platforms—notably Xianjian Technology’s IBS (CE MDR and NMPA filings) and Sino Medical’s magnesium-alloy pipelines—aim to overcome early mechanical recoil failures.
Regulatory Hurdles and Reimbursement-Driven Unit Economics
Procurement structures continue to split market economics between high-ASP Western hubs and volume-dense tender jurisdictions.
In North America, which captures more than 50% of global revenues, pricing power is managed through Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), and hospital Value Analysis Committees (VACs). Concurrently, procedural shifts into outpatient Ambulatory Surgical Centers (ASCs) are altering cath lab commercial inventory strategies.
Conversely, public tender mechanisms in Europe and Asia-Pacific have compressed device gross margins. The impact of state-driven consolidation is most evident in China's national Volume-Based Procurement (VBP). Early tenders reduced coronary stent winning bids from upwards of US$1,800 to below US$150 per unit. While this pricing recalibration severely squeezed top-line margins for non-vertically integrated players, it catalyzed procedural access—propelling China’s PCI volume past 2.0 million interventions annually and cementing high volumes for domestic and localized manufacturing leaders including JW Medical (Bluesail), MicroPort, Lepu Medical, and SINOMED. As China enters its 6th national high-value consumable VBP cycle in 2026, the structural focus is tilting toward contract award stability, verified clinical durability, and the bundling of drug-coated balloons (DCBs).
Across the European Union, the operational burden is regulatory rather than purely financial. The transitional deadlines under EU MDR 2017/745 (extended to December 2027 for Class III cardiovascular implants) have introduced Notified Body review backlogs stretching 12 to 18 months. Coupled with regional pricing clawbacks—such as the medical device payback framework in Italy—multinational manufacturers continue to rationalize legacy portfolios to absorb rising Post-Market Clinical Follow-up (PMCF) costs.
Competitive Dynamic: Consolidation vs. Specialized Disruption
Global competitive revenue remains concentrated among Tier-1 diversified conglomerates. In FY2025, Abbott’s Vascular division posted net sales of US$2.995 billion (a 5.6% year-on-year increase), supported by its XIENCE franchise. Medtronic’s Coronary & Peripheral Vascular (CPV) segment logged US$2.535 billion over the same period, led by its Resolute Onyx Frontier line. Boston Scientific reinforces this top tier with its platinum-chromium SYNERGY and PROMUS architectures.
M&A activity has actively realigned mid-tier share. On July 1, 2025, Teleflex Incorporated finalized the acquisition of Biotronik’s Vascular Intervention business, instantly absorbing the Orsiro and eucaLimus ultrathin-strut DES platforms alongside specialized percutaneous transluminal coronary angioplasty (PTCA) assets.
Concurrently, regional innovators are breaking historical geographic boundaries:
* India: Sahajanand Medical Technologies (SMT) leveraged large-scale randomized data from its TALENT trial to deploy its 60 µm Supraflex platform into Europe, competing alongside domestic peers Meril Life Sciences (BioMime 65 µm and tapered BioMime Morph) and Integris Medtech (Yukon family).
* China: SINOMED established a regulatory precedent by securing conditional US FDA Premarket Approval (PMA) for its HT Supreme / HT Infinity healing-targeted platform—the first Class III cardiovascular implant from a Chinese company to navigate the PMA pathway.
Analyst Insight: The HDIN Viewpoint
"The analytical consensus often characterizes the coronary stent market as an operational utility—a mature space subject to unrelenting tender deflation and standard manufacturing commoditization. That assessment misses the critical value-migration occurring at the intersection of stent mechanical engineering and adjunct cath-lab technologies," stated a Principal Interventional MedTech Analyst at HDIN Research.
"Our cath lab procurement audits show that stent selection is no longer isolated from procedural efficiency tools. Capital allocation is rotating toward the complete revascularization ecosystem: combining precision plaque prep via Intravascular Lithotripsy (IVL), intravascular imaging verification using OCT and high-definition IVUS, and selective 'leaving nothing behind' strategies using Drug-Coated Balloons (DCBs). The manufacturers capturing resilient operating margins through 2031 are not selling stand-alone DES hardware. They are the operators controlling end-to-end procedural workflows, defending their high ASPs in developed markets via specialized complex-PCI clinical data, while mastering local cleanroom cost bases to remain cash-flow positive under sovereign public tenders."
Key Market Players Analyzed in This Report Include:
* Abbott Laboratories (USA)
* Medtronic plc (USA / Ireland)
* Boston Scientific Corporation (USA)
* Teleflex Incorporated (USA)
* B. Braun Melsungen AG (Germany)
* Bluesail Medical Co., Ltd. / Biosensors / JWMS (China / Singapore)
* Terumo Corporation (Japan)
* Lepu Medical Technology (Beijing) Co., Ltd. (China)
* MicroPort Scientific Corporation (China)
* Sino Medical Sciences Technology Inc. [SINOMED] (China)
* Integris Medtech Limited / Translumina (India)
* Meril Life Sciences Pvt. Ltd. (India)
* Relisys Medical Devices Limited (India)
* Sahajanand Medical Technologies Ltd. [SMT] (India)
* Liaoning Yinyi Biological Technology Co., Ltd. (China)
* OrbusNeich Medical Group Holdings Limited (Hong Kong, China)
* CID S.p.A. / Alvimedica (Italy)
* iVascular SLU (Spain)
* Genoss Co., Ltd. (South Korea)
* Osstem Cardiotec Co., Ltd. (South Korea)
Sample Pages Access
Click the PDF download link under 'Related Topics' to access the sample pages of this comprehensive report.
About HDIN Research
HDIN Research focuses on providing comprehensive market consulting services. As an independent third-party consulting firm, it is committed to delivering in-depth market research and technical analysis reports across high-barrier industries, life sciences, and advanced medical technologies.
* Website: www.hdinresearch.com
* Report Link: www.hdinresearch.com/reports/162680
* Inquiries: sales@hdinresearch.com
*This market intelligence was curated by HDIN Research analysts with technical drafting assistance from AI. All data, logic, and strategic conclusions have been audited and verified by our human editorial board to ensure professional-grade accuracy.*
According to primary field audits and supply-side econometric modeling published today by HDIN Research, the global coronary stent market is valued between US$7.2 billion and US$8.2 billion in 2026. Expanding at a compound annual growth rate (CAGR) of 4.6% to 6.6%, aggregate industry revenues are projected to reach between US$9.0 billion and US$11.3 billion by 2031. Growth across the intervention sector remains anchored by an escalating global burden of cardiometabolic indications and demographic aging, with global procedural volume heavily bolstered by the Asia-Pacific territory—where annual Percutaneous Coronary Intervention (PCI) procedures in China surpassed 2.0 million cases in 2025.
Technological Moats and the Monolithic Reign of Drug-Eluting Stents
Clinical deployment metrics compiled by HDIN Research confirm that Drug-Eluting Stents (DES) command more than 98% of all percutaneous coronary revascularizations worldwide. Bare Metal Stents (BMS), constructed from unmedicated 316L stainless steel or cobalt-chromium (CoCr) structures, have fallen below 1–2% market volume due to historic 12-month in-stent restenosis (ISR) profiles tracking between 10% and 30%.
The technological baseline has consolidated around thin- and ultra-thin-strut metallic architectures (CoCr and platinum-chromium) delivering antiproliferative macrocyclic lactones ('limus class agents, including sirolimus, everolimus, zotarolimus, and biolimus A9). Multi-tiered technical moats separate established market incumbents from regional commodity producers:
* Durable vs. Bioresorbable Coatings: While durable fluoropolymer platforms such as Abbott Vascular’s XIENCE and Medtronic’s Resolute Onyx maintain clinical trust, structural innovation has rotated toward abluminal bioresorbable polymers. Platforms like MicroPort’s Firehawk (target-eluting laser grooves) and Sino Medical’s BuMA minimize systemic carrier exposure to accelerate long-term vessel healing.
* Polymer-Free Solutions for High Bleeding Risk (HBR): Solutions such as Bluesail Medical’s BioFreedom Ultra deploy biolimus A9 via micro-structured metallic surfaces without polymer carriers, securing regulatory validation for abbreviated 1-month dual antiplatelet therapy (DAPT).
* Bioresorbable Scaffolds (BRS): Following the 2017 global market withdrawal of Abbott's early thick-strut Absorb BVS, the "intervention without implantation" segment is restructuring. Lepu Medical’s NeoVas (PLLA scaffold) retains an NMPA Class III footprint in China, while next-generation metallic platforms—notably Xianjian Technology’s IBS (CE MDR and NMPA filings) and Sino Medical’s magnesium-alloy pipelines—aim to overcome early mechanical recoil failures.
Regulatory Hurdles and Reimbursement-Driven Unit Economics
Procurement structures continue to split market economics between high-ASP Western hubs and volume-dense tender jurisdictions.
In North America, which captures more than 50% of global revenues, pricing power is managed through Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), and hospital Value Analysis Committees (VACs). Concurrently, procedural shifts into outpatient Ambulatory Surgical Centers (ASCs) are altering cath lab commercial inventory strategies.
Conversely, public tender mechanisms in Europe and Asia-Pacific have compressed device gross margins. The impact of state-driven consolidation is most evident in China's national Volume-Based Procurement (VBP). Early tenders reduced coronary stent winning bids from upwards of US$1,800 to below US$150 per unit. While this pricing recalibration severely squeezed top-line margins for non-vertically integrated players, it catalyzed procedural access—propelling China’s PCI volume past 2.0 million interventions annually and cementing high volumes for domestic and localized manufacturing leaders including JW Medical (Bluesail), MicroPort, Lepu Medical, and SINOMED. As China enters its 6th national high-value consumable VBP cycle in 2026, the structural focus is tilting toward contract award stability, verified clinical durability, and the bundling of drug-coated balloons (DCBs).
Across the European Union, the operational burden is regulatory rather than purely financial. The transitional deadlines under EU MDR 2017/745 (extended to December 2027 for Class III cardiovascular implants) have introduced Notified Body review backlogs stretching 12 to 18 months. Coupled with regional pricing clawbacks—such as the medical device payback framework in Italy—multinational manufacturers continue to rationalize legacy portfolios to absorb rising Post-Market Clinical Follow-up (PMCF) costs.
Competitive Dynamic: Consolidation vs. Specialized Disruption
Global competitive revenue remains concentrated among Tier-1 diversified conglomerates. In FY2025, Abbott’s Vascular division posted net sales of US$2.995 billion (a 5.6% year-on-year increase), supported by its XIENCE franchise. Medtronic’s Coronary & Peripheral Vascular (CPV) segment logged US$2.535 billion over the same period, led by its Resolute Onyx Frontier line. Boston Scientific reinforces this top tier with its platinum-chromium SYNERGY and PROMUS architectures.
M&A activity has actively realigned mid-tier share. On July 1, 2025, Teleflex Incorporated finalized the acquisition of Biotronik’s Vascular Intervention business, instantly absorbing the Orsiro and eucaLimus ultrathin-strut DES platforms alongside specialized percutaneous transluminal coronary angioplasty (PTCA) assets.
Concurrently, regional innovators are breaking historical geographic boundaries:
* India: Sahajanand Medical Technologies (SMT) leveraged large-scale randomized data from its TALENT trial to deploy its 60 µm Supraflex platform into Europe, competing alongside domestic peers Meril Life Sciences (BioMime 65 µm and tapered BioMime Morph) and Integris Medtech (Yukon family).
* China: SINOMED established a regulatory precedent by securing conditional US FDA Premarket Approval (PMA) for its HT Supreme / HT Infinity healing-targeted platform—the first Class III cardiovascular implant from a Chinese company to navigate the PMA pathway.
Analyst Insight: The HDIN Viewpoint
"The analytical consensus often characterizes the coronary stent market as an operational utility—a mature space subject to unrelenting tender deflation and standard manufacturing commoditization. That assessment misses the critical value-migration occurring at the intersection of stent mechanical engineering and adjunct cath-lab technologies," stated a Principal Interventional MedTech Analyst at HDIN Research.
"Our cath lab procurement audits show that stent selection is no longer isolated from procedural efficiency tools. Capital allocation is rotating toward the complete revascularization ecosystem: combining precision plaque prep via Intravascular Lithotripsy (IVL), intravascular imaging verification using OCT and high-definition IVUS, and selective 'leaving nothing behind' strategies using Drug-Coated Balloons (DCBs). The manufacturers capturing resilient operating margins through 2031 are not selling stand-alone DES hardware. They are the operators controlling end-to-end procedural workflows, defending their high ASPs in developed markets via specialized complex-PCI clinical data, while mastering local cleanroom cost bases to remain cash-flow positive under sovereign public tenders."
Key Market Players Analyzed in This Report Include:
* Abbott Laboratories (USA)
* Medtronic plc (USA / Ireland)
* Boston Scientific Corporation (USA)
* Teleflex Incorporated (USA)
* B. Braun Melsungen AG (Germany)
* Bluesail Medical Co., Ltd. / Biosensors / JWMS (China / Singapore)
* Terumo Corporation (Japan)
* Lepu Medical Technology (Beijing) Co., Ltd. (China)
* MicroPort Scientific Corporation (China)
* Sino Medical Sciences Technology Inc. [SINOMED] (China)
* Integris Medtech Limited / Translumina (India)
* Meril Life Sciences Pvt. Ltd. (India)
* Relisys Medical Devices Limited (India)
* Sahajanand Medical Technologies Ltd. [SMT] (India)
* Liaoning Yinyi Biological Technology Co., Ltd. (China)
* OrbusNeich Medical Group Holdings Limited (Hong Kong, China)
* CID S.p.A. / Alvimedica (Italy)
* iVascular SLU (Spain)
* Genoss Co., Ltd. (South Korea)
* Osstem Cardiotec Co., Ltd. (South Korea)
Sample Pages Access
Click the PDF download link under 'Related Topics' to access the sample pages of this comprehensive report.
About HDIN Research
HDIN Research focuses on providing comprehensive market consulting services. As an independent third-party consulting firm, it is committed to delivering in-depth market research and technical analysis reports across high-barrier industries, life sciences, and advanced medical technologies.
* Website: www.hdinresearch.com
* Report Link: www.hdinresearch.com/reports/162680
* Inquiries: sales@hdinresearch.com
*This market intelligence was curated by HDIN Research analysts with technical drafting assistance from AI. All data, logic, and strategic conclusions have been audited and verified by our human editorial board to ensure professional-grade accuracy.*